Inventor
EVANS ELIZABETH E
US13 patents
⚠️ This page may combine multiple inventors who share the name “EVANS ELIZABETH E”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
UNIV ROCHESTER
6 patentsUS7750125B2Jul 6, 2010
Antibodies that bind to the C35 polypeptide
UNIV ROCHESTER34 citations95
US7563882B2Jul 21, 2009
Polynucleotides encoding antibodies that bind to the C35 polypeptide
UNIV ROCHESTER43 citations95
US7268207B2Sep 11, 2007
Gene differentially expressed in breast and bladder cancer, and encoded polypeptides
UNIV ROCHESTER14 citations80
US7968688B2Jun 28, 2011
Antibodies that bind to the C35 polypeptide
UNIV ROCHESTER0 citations51
US7879990B2Feb 1, 2011
Polynucleotides encoding antibodies that bind to the C35 polypeptide
UNIV ROCHESTER0 citations51
US7910551B2Mar 22, 2011
Gene differentially expressed in breast and bladder cancer and encoded polypeptides
UNIV ROCHESTER0 citations48
VACCINEX INC
6 patentsUS9828435B2Nov 28, 2017
Use of antibodies or antigen-binding fragments thereof that specifically bind semaphorin-4D to increase tumor infiltrating leukocyte frequency
VACCINEX INC22 citations94
US9243068B2Jan 26, 2016
Combination of SEMA-4D inhibitors and immunomodulators to inhibit tumors and metastases
VACCINEX INC25 citations94
US8790652B2Jul 29, 2014
Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
VACCINEX INC20 citations88
US11597765B2Mar 7, 2023
Use of semaphorin-4D binding molecules for the treatment of Rett syndrome
VACCINEX INC2 citations67
US12070500B2Aug 27, 2024
Use of semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasis
VACCINEX INC0 citations62
US10526414B2Jan 7, 2020
Use of anti-semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastases
VACCINEX INC0 citations52